Abeona Therapeutics Inc (NASDAQ:ABEO) Sellers Increased By 1.55% Their Shorts

April 17, 2018 - By Benjamin Allen

Abeona Therapeutics Inc. (NASDAQ:ABEO) Corporate Logo

Abeona Therapeutics Inc (NASDAQ:ABEO) had an increase of its shares shorted by 1.55%. In April was announced ABEO’s total 11.15M shares shorted by FINRA. That’s 1.55% up from 10.98M shares. 12 days will cost ABEO With 904,300 average volume to recover its previous position. 40.03% is Abeona Therapeutics Inc float short.

ABEO reached $20.1 on during the last trading session after $0.35 change.Abeona Therapeutics Inc. has volume of 871,593 shares. Since April 17, 2017 ABEO has risen 188.66% and is uptrending. The stock outperformed the S&P500 by 177.11%.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases.The company has $949.26 million market cap. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A.Currently it has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Total analysts of 5 have positions in Abeona Therapeutics (NASDAQ:ABEO) as follows: 5 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. The firm has $36.0 highest while $23.0 is the lowest [Target]. The average target $29.20 is 45.27% above the last ($20.1) price. Since November 2, 2017 according to StockzIntelligence Inc Abeona Therapeutics has 13 analyst reports. On Tuesday, November 21 the rating was maintained by Jefferies with “Buy”. On Thursday, November 2 the company was maintained by RBC Capital Markets. On Tuesday, January 23 the firm earned “Buy” rating by RBC Capital Markets. On Tuesday, March 20 the company was maintained by Cantor Fitzgerald. On Wednesday, February 7 the firm has “Buy” rating by Cantor Fitzgerald given. On Wednesday, November 22 the rating was maintained by H.C. Wainwright with “Buy”. On Thursday, January 4 the company was maintained by H.C. Wainwright. The stock rating was maintained by H.C. Wainwright with “Buy” on Thursday, April 12. On Thursday, February 1 H.C. Wainwright maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) rating. H.C. Wainwright has “Buy” rating and $30.0 target. On Thursday, February 8 the company was maintained by H.C. Wainwright.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: